Trial reportJournal of neurology, neurosurgery, and psychiatry1996
Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.
Trial report in Journal of neurology, neurosurgery, and psychiatry, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00270816 (Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Cyclical Administration of Interferon β-1b in Multiple Sclerosis - Comparison With Normal Dose.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.
- Interferon in relapsing-remitting multiple sclerosis.The Cochrane database of systematic reviews · 2001Pooled it
- Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis.Journal of neurology · 2006Trial
- Three subsequent single doses of gadolinium chelate for brain MR imaging in multiple sclerosis.AJNR. American journal of neuroradiology · 2003Trial
- Interferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images.Journal of neurology, neurosurgery, and psychiatry · 1999Trial
- Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 1997Trial
- Brain Barriers and Multiple Sclerosis: Novel Treatment Approaches from a Brain Barriers Perspective.Handbook of experimental pharmacology · 2022Article
- Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority.Frontiers in neurology · 2019Article
- The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence.Human brain mapping · 2016Article
- Assessment of ovarian reserve and Doppler characteristics in patients with multiple sclerosis using immunomodulating drugs.Journal of the Turkish German Gynecological Association · 2009Article
- The effect of interferon beta-1b on size of short-lived enhancing lesions in patients with multiple sclerosis.Expert opinion on biological therapy · 2008Article
- Interferon-beta and adhesion molecules (E-selectin and s-intracellular adhesion molecule-1) are detected in sera from patients with retinal vasculitis and are induced in retinal vascular endothelial cells by Toll-like receptor 3 signalling.Clinical and experimental immunology · 2007Article
- Interferons in relapsing-remitting multiple sclerosis: are there benefits from long-term use?CNS drugs · 2004Review
- "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 1998Review
- More immunotherapy for multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 1996Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as measured by a reduction in the number and volume of Gd enhancing lesions on monthly MRI. The study also evaluated the effect on six-monthly T2 weighted abnormality and relapse frequency.
methodsAfter a baseline scan and a six month pretreatment period, 68 patients were randomly assigned to receive either 3 MIU or 9 MIU of interferon-beta-1a by subcutaneous injection three times a week for six months. All patients were examined by Gd enhanced MRI every month in both pretreatment and treatment periods. The evaluation of Gd enhancing lesions was performed blind at the end of the study.
resultsThe mean number of Gd enhancing lesions was higher during the pretreatment period than during treatment. This difference was statistically significant for the two different dose subgroups (3.5 v 1.8, P < 0.001 for the 3 MIU group and 2.4 v 0.9, P < 0.001 for the 9 MIU group, corresponding to a reduction of 49% and 64% respectively). The mean volume of Gd enhancing lesions also significantly decreased by 61% (3 MIU group) and 73% (9 MIU group). These reductions were evident only after the first month of treatment. The six-monthly rate of new lesions as seen in T2 weighted images showed a similar trend of reduction with treatment (65% and 70% respectively). Lesion volume on T2 scans significantly increased during the pretreatment period whereas it remained almost stable during the treatment period in both groups. Clinical relapse rate was significantly reduced by treatment (53% for the 3 MIU group, P < 0.001; 69% for the 9 MIU group, P < 0.001).
conclusionInterferon-beta-1a seemed effective in reducing disease activity in relapsing-remitting multiple sclerosis at both the doses used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.